|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CNBC's Jim Cramer seconds Nvidia's call for more computing and explains why investors have reason to believe in the stock's bottom. The "Mad Money" host also sits down with the CEOs of Johnson & Johnson and Zoetis. In the lightning round, Cramer revealed his pick between two top gaming stocks.
Johnson & Johnson Chairman and CEO Alex Gorsky speaks to his company's partnership with Apple, deal to buy Auris Health and more in an interview with CNBC's Jim Cramer. The pharmaceutical company is collaborating with Apple to build out the health-care capabilities of its Watch. Gorsky also briefly addresses the company's scandal surrounding its baby powder product.
Announcement: Moody's announces completion of a periodic review of ratings of Pfizer Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Pfizer Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Johnson & Johnson and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Biotech stocks got some reprieve in this week amid the release of earnings, clinical trial results presentations and positive FDA actions. Among the noteworthy developments of the week: The FDA panel ruling ...
Bristol-Myers Squibb could still be in play, an analyst said Friday, suggesting Johnson and Johnson, Pfizer or Amgen could make a bid. That would break up Bristol's takeover of Celgene.
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth drivers On its fourth-quarter earnings conference call, GlaxoSmithKline (GSK) highlighted the prioritization of R&D (research and development)
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
Pfizer Inc NYSE:PFEView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for PFE with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding PFE totaled $14.08 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. PFE credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Veracyte's CEO keeps pushing for constant innovation at the company she helped navigate through a stormy beginning.
Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson. The drug, tested on early stage prostate cancer that does not respond to hormonal therapy, was shown to be safe to use with only fatigue as the most serious side effect, Bayer said on Thursday, citing a phase-three study that could be decisive for regulatory approval. Given the cancer is not yet spreading and patients are still relatively unburdened by the disease, a drug's tolerability is a key concern for the generally elderly men taking it, said Robert LaCaze, Bayer's head of oncology.
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
A combination of factors is helping push U.S. equities to fresh highs, with the Dow Jones Industrial Average rising to levels not seen since early December on Wednesday.These include hopes of a U.S.-China trade deal (with President Trump reportedly pushing back a tariff deadline), optimism over a budget deal in Congress (hopefully avoiding another government shutdown) and ongoing ease with the Federal Reserve's newly dovish stance.The bulls are going from strength to strength, shifting the focus of their buying as the post-December uptrend matures and changes its nature. From a focus on beaten-down big-cap technology stocks, new areas are piquing the interest of value hunters in areas like energy, industrials and healthcare.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best ETFs You Can Buy With that in mind, here are 10 hot stocks to watch as they lead the market higher: Philips 66 (PSX)Energy stocks like Philips 66 (NYSE:PSX) are coming back to life as crude oil starts to stir, with shares breaking out of a two-month resistance range as the 20-day moving average extends a rise above the 50-day average. Shares were recently upgraded by analysts at Tudor Pickering.The company will next report results on May 10 before the bell. Analysts are looking for earnings of $1.1 per share on revenues of $24.7 billion. When the company last reported on Feb. 8, earnings of $4.87 beat estimates by $1.98 per share on revenues of nearly $29 billion. Hess (HES)Hess (NYSE:HES) is another energy stock to watch, with shares moving to challenge the 200-day moving average to cap what looks like an inverse head-and-shoulders reversal pattern that traces a move to back to the early October high near $75. The company, along with ExxonMobil (NYSE:XOM) recently announced positive results from two offshore wells in Guyana. * 10 'Buy-and-Hold' Stocks to Own Forever The company will next report results on May 1 before the bell. Analysts are looking for a loss of 21 cents per share on revenues of $1.59 billion. When the company last reported on Jan. 30, a loss of 31 cents per share beat estimates by 7 cents on a 30.3% rise in revenues. AMD (AMD)AMD (NASDAQ:AMD) shares are consolidating a recent breakout, with the 20-day moving average extending away from its 50-day and 200-day moving averages presaging a break of prior highs and a challenge of the September levels. This would be worth a gain of more than 50% from here. In its most recent quarter, despite weak guidance from management, investors focused on a 9% increase in revenues for its computing and graphics segment thanks to a ramp in its Ryzen processors.The company will next report results on April 30 after the close. Analysts are looking for earnings of 2 cents per share on revenues of $1.25 billion. When the company last reported on Jan. 29, earnings of 8 cents per share matched estimates on a 5.9% rise in revenues. Microsoft (MSFT)Microsoft (NASDAQ:MSFT) shares look ready to emerge from a sloppy looking downward channel that started back in October with a break above a resistance line near $108. Such a break would set up a challenge of the early December high near $112, which would be worth a gain of 5% from here. * 10 Stocks That Every 20-Year-Old Should Buy The company will next report results on April 25 after the close. Analysts are looking for earnings of $1 per share on revenues of $29.9 billion. When the company last reported on Jan. 30, earnings of $1.10 beat estimates by a penny on a 12.3% rise in revenues. General Dynamics (GD)General Dynamics (NYSE:GD) shares are holding steady above their 20-day and 50-day moving averages, setting up a run at the prior highs near $185, which coincides with the 200-day moving average. Defense stocks have constantly been listed as hot stocks amid fresh tensions with Iran and steady budgetary support from the Trump White House and Congress.The company will next report results on May 1 before the bell. Analysts are looking for earnings of $2.45 per share on revenues of $9.3 billion. When the company last reported on Jan. 30, earnings of $3.07 per share beat estimates by 8 cents on a 25.4% rise in revenues. Deere (DE)Deere (NYSE:DE) is strongly tied to the fate of U.S.-China trade negotiations, given its focus on heavy machinery as well as agriculture equipment used for U.S. food exports. As such, shares are consolidating near prior highs set in early 2018. Watch for an upside breakout following the release of confidence guidance from management. * 7 Reasons to Own Coca-Cola Stock The company will next report results on Feb. 15 before the bell. Analysts are looking for earnings of $1.8 per share on revenues of $6.9 billion. When the company last reported on Nov. 21, earnings of $2.30 per share missed estimates by 15 cents on a 17.6% rise in revenues. DR Horton (DHI)DR Horton (NYSE:DHI) shares have climbed back up and over their 200-day moving average, setting the stage for a sustained move to test the prior high set in August. In its most recent post-earnings call, management noted that buyer traffic remained strong -- raising hopes for a strong spring selling season.The company will next report results on April 26 before the bell. Analysts are looking for earnings of 86 cents per share on revenues of $4 billion. When the company last reported on Jan. 25, earnings of 76 cents per share missed estimates by a penny on a 5.6% rise in revenues. Johnson & Johnson (JNJ)Johnson & Johnson (NYSE:JNJ) shares are extending above their 50-day and 200-day moving averages, looking ready for a run at the prior highs as worries about a baby powder lawsuit fade. The company recently unveiled a plan to buy robotics company Auris Health for roughly $3.4 billion. * 7 Reasons Stock Buybacks Should Be Illegal The company will next report results on April 23 before the bell. Analysts are looking for earnings of $2.1 per share on revenues of $19.7 billion. When the company last reported on Jan. 22, earnings of $1.97 per share beat estimates by 2 cents on a 1% rise in revenues. Under Armour (UAA)Under Armour (NYSE:UAA) shares have bounded above their 200-day moving average to close in on levels not seen since early December, capping a rise of 33% from its recent lows. While shares remain mired in a three-year-old sideways range, watch at the very least for a retest of prior channel highs near $24, which would be worth around a 10% gain from here.The company will next report results on May 14 before the bell. The company last reported results on Feb. 12, with earnings of 9 cents per share beating estimates by 5 cents on a 1.5% rise in revenues. The company remains in turnaround mode here at home, with revenues falling 6% in North America in the most recent quarter. But international growth remains a bright spot, up 24%. Freeport-McMoRan (FCX)Shares of Freeport-McMoRan (NYSE:FCX) are looking ready to emerge from a multi-month basing pattern going back to October, with the 20-day moving average extending a move above its 50-day moving average as the new uptrend gains momentum. The company was recently upgraded by Morgan Stanley analysts citing expectations that the company is likely to see an earnings boost from higher copper prices. * 7 Athletic Stocks That Could Run Higher The company will next report results on April 23 before the bell. Analysts are looking for earnings of 10 cents per share on revenues of $3.8 billion. When the company last reported on Jan. 24, earnings of 11 cents per share missed estimates by 8 cents on nearly a 27% drop in revenues.As of this writing, William Roth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 U.S. Stocks That Are Coming to Life Again * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 5 Tips to Become a Better Stock Trader Compare Brokers The post 10 Hot Stocks Leading the Market's Blitz Higher appeared first on InvestorPlace.
In the almost seven years that Johnson & Johnson (NYSE:JNJ) CEO Alex Gorsky has been in the top job, JNJ stock has achieved a cumulative total return of 155.5% (through Feb. 12). Gorsky took charge of the large-cap healthcare company on April 26, 2012. He's managed to deliver an annualized total return of 14.7%.Source: Shutterstock Shareholders must be pleased with their returns. Does that mean Gorsky's earned his pay as CEO?Maybe. Maybe not. InvestorPlace - Stock Market News, Stock Advice & Trading TipsIf we lived our lives in a vacuum, Gorsky's performance would be enough to answer "yes" to the question. However, we don't. Johnson & Johnson, like all publicly traded stocks, have benchmarks to live up to. No, I'm not saying that it has to beat the S&P 500 index and its peers every year, but over the long haul, JNJ stock ought to at least keep up with them. * 10 Best Dividend Stocks to Buy for the Next 10 Months Over the same period, the SPDR S&P 500 ETF (NYSEARCA:SPY) and the iShares US Pharmaceuticals ETF (NYSEARCA:IHE) achieved cumulative total returns of 128.9% and 99.7% respectively. So, in terms of performance, JNJ stock has easily met and exceeded shareholder expectations. From that vantage point, It's easy to how shareholders might view Gorsky's compensation as irrelevant, but it's not. Why?What happens if JNJ stock underperforms over the next seven years relative to the index and its peers? All of a sudden paying a person $29 million a year doesn't seem so smart; especially when you consider that Johnson & Johnson could get a similar result at half that fat paycheck.Big corporations like to throw out the rationalization that they have to provide this level of compensation to remain competitive. It's a bald-faced lie. There are plenty of qualified candidates in the U.S. that could handle the job at half the compensation. I'm sure of it. The truth is, if CEO compensation were an investable stock, anyone who invested in those shares between 1978 and 2017, would be wealthy. "CEO compensation has grown far faster than stock prices or corporate profits. CEO compensation rose by 979% (based on stock options granted) or 1,070% (based on stock options realized) between 1978 and 2017," Fast Company reported in August 2018. "The corresponding 637% growth in the stock market (S&P index) was far lower."You can debate the relevance of these numbers all you want but Alex Gorsky, like most CEOs, is replaceable. How Much Does Gorsky Make?I won't bore you with the details regarding salary, cash bonuses, pension plans, etc. I'm merely going to provide a table that shows how many of Gorsky's stock and option awards have vested since becoming CEO in 2012. You can decide if the largess amassed is worth it. Alex Gorsky's Stock Vested 2013-2017Year Stock Awards Value Today 2017 151,654 $20,345,901 2016 114,875 $15,411,630 2015 63,716 $8,548,139 2014 12,058 $1,617,701 2013 9,981 $1,339,051 2012 20,791 $2,789,321 Total 373,075 $50,051,743Source: SEC Corporate FilingsI guess $50 million doesn't seem like a lot over six years for a CEO of a $360 billion company. And it isn't. However, when you consider there are several candidates at JNJ who could do the job, it's a lot of money going out the door for someone who essentially won the CEO lottery.Oh, and one last thing. * Buy These 5 Stocks to Play the Megatrend of the Century As of fiscal 2017, Gorsky had 2.8 million stock options, both exercisable and unexercisable, at prices between $62 and $116, so they're all in the money. Were he to exercise all of the options at today's stock price, they'd be worth $376 million. Is Gorsky Earning His Pay?As I noted in kicking off this piece, shareholders probably don't care about overpaying Gorsky, given the returns of JNJ stock since he became CEO. However, like America, if you don't speak up about what's wrong with the country, you get what you deserve. Eventually, Johnson & Johnson stock is going to revert to the mean and when it does, Alex Gorsky won't be sitting nearly as pretty. As of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 U.S. Stocks That Are Coming to Life Again * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 5 Tips to Become a Better Stock Trader Compare Brokers The post Is Johnson & Johnson CEO Alex Gorsky Earning His Pay? appeared first on InvestorPlace.
In what could be called an unexpected and pleasant surprise this week for Johnson & Johnson (JNJ), an FDA panel voted overwhelmingly in favor of approval for esketamine, trade name Spravato, for treatment-resistant depression (TRD). Warning! GuruFocus has detected 6 Warning Signs with GOLD. Esketamine is the molecular mirror image of the sedative ketamine, often prescribed off-label for severe cases of depression involving the risk of suicide.
J&J's latest acquisition might appear to threaten its partnership with Alphabet to develop robotic surgical systems. But another player could be impacted even more.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 13) Abbott Laboratories (NYSE: ABT ) Ionis Pharmaceuticals ...
Pfizer holds a lead in the erectile dysfunction market even as generics erode sales of its once-blockbuster male libido treatment, Viagra. According to GoodRx, 65 percent of ED prescriptions filled from Dec. 1, 2018, to Jan. 31, 2019, were for Viagra or its generic version. Pfizer has been able to maintain a significant share in the erectile dysfunction market thanks in part to launching its own generic version of the blue, diamond-shaped pill.
Siddhartha Mukherjee, the cancer geneticist and Pulitzer Prize-winning writer who is working on a novel way to expand immunotherapies for blood cancers, has raised $42m for his start-up Vor Biopharma. to attack cancer, by disabling blockers inside the body.
Johnson & Johnson’s Ethicon unit has reached a deal to buy medical technology firm Auris Health Inc. for about $3.4 billion in cash, expanding J&J’s push into the use of robotic technology for medical procedures and surgery. J&J said Wednesday that Auris’s technology will help it develop a digital solution addressing different parts of patients’ lung-cancer treatment. If certain milestones are reached, Auris could also receive as much as $2.35 billion more in the deal.
Imerys Talc America, the U.S. unit of French group Imerys SA, said it filed for bankruptcy because it lacks the financial clout to defend against nearly 15,000 lawsuits over its talc mineral product, which is also used in cosmetics. Imerys said that while it continued to believe the lawsuits are without merit, the prospect of rising settlement and defense costs over the next few years prompted the decision to file for bankruptcy. In July, a Missouri jury ordered J&J to pay a record $4.69 billion (3.65 billion pounds) to 22 women who said asbestos in talc caused ovarian cancer.
The unit of Paris-based Imerys SA and two other subsidiaries filed for Chapter 11 protection in Delaware Wednesday, citing the more than 14,000 claims the company faces in U.S. courts. Most have been brought by women alleging Imerys’s talc caused their ovarian cancer. It will also corral the cases under a single judge and allow Imerys to pressure plaintiffs to accept lower settlements.
The company filed for chapter 11 protection Wednesday after spending tens of millions of dollars to defend itself against lawsuits alleging its talcum powder causes ovarian cancer and mesothelioma. The talc supplier faces claims from more than 14,600 people, a number that has grown dramatically in recent years in the wake of large verdicts against Imerys and baby powder maker Johnson & Johnson.
Jim Cramer sits down with Johnson & Johnson Chairman and CEO Alex Gorsky, who speaks to his company's partnership with Apple, deal to buy Auris Health and more.